



## 2018 Annual General Meeting

June 17, 2019  
Venlo, the Netherlands



1

## Opening

Dr. Håkan Björklund  
Chairman of the Supervisory Board



2

Managing Board Report for the year ended  
December 31, 2018 (“Calendar Year 2018”)



## 2018 Annual General Meeting

June 17, 2019

Venlo, the Netherlands

**Peer M. Schatz**  
Chief Executive Officer

## Disclaimer

**Safe Harbor Statement:** This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

**Regulation G:** QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

**GeneReader NGS System:** The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

## THE BUILDING BLOCKS OF LIFE: DNA AND RNA

## CUSTOMERS RELY ON QIAGEN FOR MOLECULAR TESTING SOLUTIONS



- QIAGEN: World leader in molecular testing solutions that advance science and improve outcomes for patients

# ADDRESSING THE WORLD'S MOST PRESSING CHALLENGES



## Academia

How can we achieve scientific breakthroughs even faster?



## Pharma

How can we develop better and safer drugs?




## Applied Testing

How can we improve public safety?



## Molecular Diagnostics


How can we further improve outcomes for patients?



● Expanding range of customers want to benefit from the value of molecular insights


## QIAGEN customer classes

2018 net sales (% of total QIAGEN sales)




## Product portfolio

2018 net sales (% of total QIAGEN sales)



## Global presence

2018 net sales (% of total QIAGEN sales)



- A most trusted brand found in virtually every lab worldwide
- True hybrid across continuum from Life Sciences to Molecular Diagnostics
- Netherlands holding company, listed on NYSE and Frankfurt Stock Exchange
- ~5,000 employees in over 35 countries

● World leader in molecular testing enabling customers to transform biological samples into valuable insights



## Levers

Sales

Sample to Insight  
portfolio strength

Operational efficiency

Disciplined  
capital allocation

## 2018 achievements

### Delivering on targets

- Applying novel approaches to customer engagement
- Focusing portfolio (e.g. China strategy and veterinary assays divestment)



### Emerging disruptive portfolio

- QuantiFERON-TB: +21% CER growth, new automation partners
- QIASymphony: >2,300 cumulative placements
- Personalized Healthcare: Winning pharma CDx deals
- NGS: Exceeded >\$140 million portfolio sales
- New platforms: QIAstat-Dx (syndromic testing) and NeuMoDx (integrated lab testing)



### Track record of improving operational efficiencies

- 27% adjusted operating income margin
- Industry-leading adjusted gross margin
- Heavily investing in leading digital capabilities




### Sustained commitment to further increase returns

- Completed half of current \$200 million share repurchase plan
- Consistent M&A strategy focused on targeted acquisitions



● Delivering on commitments for sales growth, portfolio expansion, operational efficiency and capital allocation

## Life Sciences customer class



- 2018 sales of \$770 million
- Recognized innovator supporting breakthrough science
- Ability to translate innovations into commercial products



Academia



Pharma



Applied Testing



## Selected products

### Sample technologies

- >5,000 protocols
- ~300 different kit types
- Liquid biopsy, tissue, blood, cells, plants, microbiome, other

### Assay technologies

- Real-time PCR
- Digital PCR
- Next-generation sequencing

### Instruments

- QIAcube
- QIASymphony
- QIAexcel
- RotorGene Q

### Bioinformatics

- Ingenuity Pathway Analysis (IPA)
- Genomics Workbench / Server
- Microbial Pro Suite / RNA-seq
- Microbial Epigenetics

- Enabling customers to advance science with differentiated molecular testing technologies

## Case study: Industry-leading portfolio for any sequencer

- Advances in QIAGEN's Universal NGS portfolio
  - Assay solutions based on proprietary Digital NGS technology
    - Target enrichment
    - Library preparation
  - Bioinformatics
- New: RNA-seq with QIAseq FastSelect
  - Efficient depletion of scientifically irrelevant RNAs
- Expanding immuno-oncology (I-O) presence
  - QIAseq TMB panel launch: Most advanced I-O biomarkers
  - New bioinformatics options (QCI) for I-O research
  - Developing I-O assay and CDx portfolios with pharma partners

## Universal NGS (UNGS) solutions




## ● Universal NGS portfolio: Capturing attractive growth in assay technologies and bioinformatics

## Case study: Reinventing digital PCR



- Acquisition of digital PCR technology from Formulatrix
  - New instrument range in late-stage development by QIAGEN
  - Commercialization planned for 2020
- Fully integrated microplate-based platform series
  - Greatly simplified workflow
  - Fast: <90 minutes protocols vs. current >300 minutes
  - High multiplexing: 5-plex vs. current 2-plex
  - Large throughput flexibility
- Differentiated enhancement to QIAGEN portfolio
  - Fits well into QIAGEN platform and technology portfolio
  - Significant synergies with quantitative PCR franchise
- Access to fast-growing market opportunity
  - Current market size: >\$200 million, >20% CER growth
  - Plans to expand into clinical applications


## New QIAGEN digital PCR platforms



## ● Digital PCR: Fully integrated platforms being prepared for 2020 launch

(1) On January 31, 2019, QIAGEN acquired the digital PCR assets of Formulatrix, Inc., for \$125.0 million in cash and up to about \$135.9 million in future milestones.


## Molecular Diagnostics customer class



- 2018 sales of \$732 million
- Focus on high-growth, high-demand opportunities
- Significant automation portfolio expansion in 2018
- Multi-year assay menu development under way




Molecular Diagnostics



### Selected products

Sample technologies	Assay technologies	Instruments	Bioinformatics
<ul style="list-style-type: none"> <li>■ Tissue</li> <li>■ Blood</li> <li>■ Liquid biopsy</li> <li>■ Swabs, other</li> </ul>	<ul style="list-style-type: none"> <li>■ Indication areas                             <ul style="list-style-type: none"> <li>□ Oncology</li> <li>□ Immune modulation</li> <li>□ Infectious diseases</li> </ul> </li> <li>■ Technologies: QFT, PCR, NGS</li> </ul>	<ul style="list-style-type: none"> <li>■ QIASymphony RGQ</li> <li>■ GeneReader NGS System</li> <li>■ QIAstat-Dx</li> <li>■ NeuMoDx</li> </ul>	<ul style="list-style-type: none"> <li>■ QIAGEN Clinical Insight (QCI)                             <ul style="list-style-type: none"> <li>□ Hereditary diseases</li> <li>□ Somatic and germline cancers</li> <li>□ All diseases</li> </ul> </li> </ul>

● Improving outcomes for patients and increasing lab efficiencies with superior molecular diagnostics




- Most comprehensive portfolio to address demands for various molecular testing technologies


## Case study: Next-generation system for syndromic testing

- Addressing a ~\$800 million market opportunity
- EU launch in mid-2018 after STAT-Dx acquisition<sup>(1)</sup>
- U.S. launch under way after May 2019 FDA clearance
- Differentiation: Ease of use, PCR-based system and cost efficiency

Selected U.S. assay menu plans



Selected CE assay menu plans



## QIAstat-Dx



	QIAstat-Dx	Comp. B	Comp. G
Real-time PCR quantification	✓	No	No
Display of curves / Ct values	✓	No	No
Time to result	~1 hour	~1 hour	~1.5 hours
Reagent reconstitution	Not required	Required	Not required
Hands-free sample preparation	✓	No	No

● QIAstat-Dx: Next-generation system for reliable, fast and cost-effective diagnosis of complex syndromes

## Case study: Disruptive PCR technology for integrated testing

- Entering ~\$2.7 billion market
- Synergistic with QIAGEN's strong positioning in this lab testing segment
- 2018 EU launch, complements QIASymphony (modular segment)
- Differentiation: Speed, full random access, walk-away, on-board storage
- Contingent full acquisition of NeuMoDx: Latest by mid-2020<sup>(1)</sup>

Selected CE assay menu plans

2018	2019
	Trich + MG
	HIV
	FluA / B-RSV
	HPV
	EBV
	GAS
	CMV
HCV	HCV
HBV	HBV
CT/NG	CT/NG
GBS	GBS

## NeuMoDx 96 / 288



	NeuMoDx	Comp. R	Comp. H
True random access	✓	No	No
Time to result	40 min	<3.5 h	~3.5 h
Max. sample loading	Up to 288	Up to 350	Up to 120
Walk-away time	~7 hours	2 x 4 hours	~4 hours
Footprint (width x depth)	183x109 cm	429x129 cm	193x82cm

## ● NeuMoDx: Bringing the simplicity of clinical chemistry testing automation to Molecular Diagnostics labs





## 2019 Precision Medicine highlights

- *therascreen* PIK3CA and FGFR: First FDA approvals for key CDx
  - Novel therapies qualifying patients for prescription drugs
- LabCorp joins QIAGEN's Day-One Lab Readiness program

## *therascreen* U.S.-approved CDx assay portfolio

	Drug	Partner
KRAS	Vectibix®	
EGFR	VIZIMPRO®	
	Iressa®	
	GILOTRIF®	
<b>NEW</b>	PIK3CA	Piqray®
<b>NEW</b>	FGFR	BALVERSA™


## New U.S. CDx assays addressing critical cancers



● Precision Medicine: Increasing range of QIAGEN companion diagnostics with two new FDA approvals

## Looking ahead to 2019:

Delivering on growth opportunities from a dynamic and disruptive portfolio of Sample to Insight solutions



## Green development

- Conversion of ~150 tons from air freight to sea freight during 2018
- Installation of energy recovery and control systems to reduce usage

## Non-financial information

- Reporting information based on:
  - Sustainability Reporting Standards (GRI) and SASB standards

## Corporate citizenship

- ~1,500 hours of volunteer work by U.S. colleagues in 2018



## Global workforce

- ~5,000 employees
- ~70 nationalities
- ~50% women

## Diversity

- Diversity Ambassador program introduced with >20 leaders worldwide
- Advocating diversity with training programs

## Employee development

- ~4,900 employees participated in virtual, instructor-led and e-learning courses
- Work-life balance with sabbatical programs and flexible work hours



**About QIAGEN N.V.**

---

- Organized under the laws of Netherlands
- Listed on NYSE (New York)
- Member of TecDAX Index (Frankfurt) and MDAX

**Endorsing relevant principles**


---

- Application of Dutch Corporate Governance Code
- NYSE Corporate Governance Rules



## Sample to Insight

### Analyst ratings




### 2018 IR activities

- Private shareholder day: ~25 participants
- Institutional conferences: ~30 events
- Individual meetings: ~650 meetings
- Analyst & Investor Day: June 20, 2019




## QIAGEN share price development – Frankfurt Stock Exchange (euros)





# 2018: QIAGEN shares (NYSE)

QIAGEN share price development – NYSE (U.S. dollars)







Sample to Insight portfolio driving transformation

---

Moving ahead on sustainable growth and leverage trajectory

---

Building a strong foundation to excel toward 2020 and beyond

---

Committed to higher returns and greater value creation

---



## 2018 Annual General Meeting

June 17, 2019

Venlo, the Netherlands

**Roland Sackers**

**Chief Financial Officer**

**Safe Harbor Statement:** This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

**Regulation G:** QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

**GeneReader NGS System:** The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

## 1 Achieved 2018 target for net sales, exceeded on adjusted EPS


- +6% net sales growth (+6% CER vs. ~+6-7% CER outlook)
- \$1.34 adjusted EPS (\$1.35 CER vs. ~\$1.33-1.34 CER outlook)
- 27% adjusted operating income margin up one percentage point vs. 2017
- Operating cash flow rises 25% to \$359.5 million in 2018

## 2 Delivering growth from differentiated Sample to Insight portfolio

- QuantiFERON-TB: 21% growth, full automation launched (DiaSorin, front end)
- NGS: Exceeded 2018 goal of \$140 m, 2019 goal ~\$190 m
- QIAasymphony: Exceeded 2018 goal of 2,300 instruments, 2019 target of >2,500
- QIAstat-Dx: Very promising start in Europe, U.S. entry planned for 2019
- NeuMoDx: First placements in Europe with very positive feedback
- Digital PCR: Preparing for 2020 launch of new integrated systems


## Net sales

(In \$ millions, at actual rates)



## Adjusted EPS<sup>(1)</sup>

(In \$ per share)



Refer to accompanying tables for reconciliation of reported to adjusted figures.

(1) Weighted number of diluted shares (FY 2018: 233.5 million, FY 2017: 233.0 million).

CER – Constant exchange rates

p.p. – percentage points

PCR – Polymerase chain reaction

NGS – Next-generation sequencing

UNGS – Universal NGS

In \$ millions, unless indicated  
(Diluted EPS in \$ per share)

	Full-year		
	2018	2017	Change
Net sales	1,501.8	1,417.5	6% (6% CER)
<i>Gross profit margin</i>	67%	65%	
<i>Adjusted gross profit margin</i>	71%	71%	
Operating income	266.6	153.4	74%
<i>Operating income margin</i>	18%	11%	
Adjusted operating income	403.3	371.5	9%
<i>Adjusted operating income margin</i>	27%	26%	
Net income	190.4	40.4	371%
Adjusted net income	311.9	295.3	6%
Tax rate	16%	NM	
Adjusted tax rate	19%	18%	
EPS (\$ per share) <sup>(1)</sup>	\$0.82	\$0.17	
Adjusted EPS (CER) <sup>(1)</sup>	\$1.34 (\$1.35)	\$1.27	

## ● Full-year 2018: Adjusted operating income margin rises to 27% of sales on efficiency gains

Refer to accompanying tables for reconciliation of reported to adjusted figures.

(1) Weighted number of diluted shares (FY 2018: 233.5 million, FY 2017: 233.0 million).

CER – Constant exchange rates

NM - Not meaningful

FY 2018 net sales: \$1,501.8 million

	Sales (In \$ m)	% change	% CER change	% of sales
Consumables and related revenues	\$1,315	+6%	+6%	88%
Instruments	\$186	+7%	+6%	12%
Molecular Diagnostics <sup>(1)</sup>	\$732	+7%	+8%	49%
Applied Testing	\$137	0%	0%	9%
Pharma	\$291	+6%	+5%	19%
Academia	\$342	+6%	+5%	23%






## FY 2018: Gains in Molecular Diagnostics, Pharma and Academia customer classes drive 6% CER growth

(1) CDx co-development sales (FY 2018: \$58 million, +36%, +34% CER); U.S. HPV sales (FY 2018: \$19 million vs. FY 2017: \$28 million).  
Sales figures and sales contributions at actual FX rates      Tables may contain rounding differences      CDx – Companion diagnostics

FY 2018 net sales: \$1,501.8 million

	Sales (In \$ m)	% change	% CER change	% of sales
Americas	\$693	+6%	+6%	46%
Europe / Middle East / Africa	\$490	+6%	+6%	33%
Asia-Pacific / Japan	\$315	+6%	+5%	21%



● Full-year 2018: Solid growth across all regions (+6% CER) and top 7 emerging markets (+11% CER)

Top 7 EGM (FY 2018: +5% / +11% CER / 16% of sales); Rest of the world (FY 2018: Less than 1% of net sales)  
 Sales figures and sales contributions at actual FX rates      Tables may contain rounding differences



## 2018: Reconciliation adjusted results (U.S. GAAP)

In \$ millions (Except EPS)  
(unaudited)

	Net sales	Gross profit	Operating income	Pretax income	Income tax	Tax rate	Net income	Diluted EPS
<b>Full-year 2018</b>								
Reported results	1,501.8	1,001.0	266.6	225.7	-35.4	16%	190.4	0.82
<i>Adjustments</i>								
Business integration, acquisition and restructuring-related items (including litigation)	0.1	4.3	41.0	41.0	-11.0		29.9	0.13
Purchased intangibles amortization		56.7	95.8	95.8	-24.8		71.0	0.30
Non-cash interest expense charges				35.6			35.6	0.15
Other special income and expense				-12.6	-2.4		-15.0	-0.06
Total adjustments	0.1	61.0	136.7	159.8	-38.2		121.5	0.52
<b>Adjusted results</b>	<b>1,501.9</b>	<b>1,062.0</b>	<b>403.3</b>	<b>385.5</b>	<b>-73.6</b>	<b>19%</b>	<b>311.9</b>	<b>1.34</b>

### ● Full-year 2018: Solid sales and adjusted EPS growth in line with outlook


(1) Weighted number of diluted shares (FY 2018: 233.5 million).

Table may have rounding differences. Net income and diluted EPS based on net income attributable to owners of QIAGEN N.V.



## Consolidated Income Statements for the year ended December 31, 2018 Reconciliation of net income from U.S. GAAP to IFRS

(In \$ millions)



(1) Under U.S. GAAP, Upper Calls are recorded in equity at historical cost. Under IFRS, Upper Calls are liabilities subject to fair value remeasurements..

(2) IFRS tax results differ from U.S. GAAP for deferred tax on share-based compensation, interest carryforward and intercompany transactions.

## Consolidated Income Statements for the year ended December 31, 2018

In \$ millions (Except per share data)	U.S. GAAP 2018	IFRS 2018	Difference (U.S. GAAP vs. IFRS)
Net sales	1,501.8	1,501.8	
Gross profit	1,001.0	992.8	8.2
Income from operations	266.6	272.5	-5.9
Net income	190.4	104.9	85.5
Earnings per share attributable to equity holders of QIAGEN N.V.			
Weighted average number of common shares, basic	226.6	226.6	
Basic in \$ per share	\$0.84	\$0.46	\$0.38
Weighted average number of common shares, diluted	233.5	233.5	
Diluted in \$ per share	\$0.82	\$0.45	\$0.37

- Full-year 2018 results: Institutional investors worldwide assess QIAGEN on U.S. GAAP results

## Balance sheet data

(As of December 31 )


	2018	2017
Group liquidity (In \$ millions)	1,394	1,017
Net debt (In \$ millions)	781	743
Shareholder equity ratio	46%	50%
Leverage ratio <sup>(1)</sup>	1.4x	1.5x

## Cash flow

(In \$ millions)

	FY 2018	FY 2017
Net cash provided by operating activities <sup>(2)</sup>	359.5	286.8
Purchases of property, plant and equipment	-109.8	-90.1
Free cash flow <sup>(2)</sup>	249.7	196.7

## Leverage ratio<sup>(1)</sup>



## ● Full-year 2018: Operating cash flow rises 25% to \$359.5 million


(1) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA.

(2) Net cash provided by operating activities for FY 2018 included \$30 million payment for pre-paid royalties for Natera partnership




- Disciplined capital allocation: Ongoing commitment to increasing returns

## Structure as of March 31, 2019



## Maturities of debt instruments

(In \$ millions)



### Convertible notes (total volume approx. \$1,197 m):

\$297 m 0.875% due 2021 (\$32.06 effective conversion price)  
 \$400 m 0.500% due 2023 (\$50.97 effective conversion price)  
 \$500 m 1.000% due 2024 (\$52.16 effective conversion price)

### Schuldscheindarlehn (total volume approx. \$321 m):

€34.5 m due 2021 (fix 0.40%, floating 6mEURIBOR + 0.40%)  
 €111 m due 2022 (fix 0.68%, floating 6mEURIBOR + 0.50%)  
 \$45.0 m due 2022 (floating LIBOR + 1.2%)  
 €95.0 m due 2024 (fix 1.09%, floating 6mEURIBOR + 0.70%)  
 €14.5 m due 2027 (fix 1.61%)

### U.S. Private Placement (total volume approx. \$400 m):

\$73 m 3.19% notes due 2019  
 \$300 m 3.75% notes due 2022  
 \$27 m 3.90% notes due 2024



# Employees as of December 31, 2018

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total Q4 2018	Total Q4 2017	Change
Production	277	656	134	1,067	1,020	5%
R&D	231	775	50	1,056	985	7%
Sales	559	762	669	1,990	1,883	6%
Marketing	77	155	76	308	278	11%
Administration	86	322	123	531	491	8%
<b>Total</b>	<b>1,230</b>	<b>2,670</b>	<b>1,052</b>	<b>4,952</b>	<b>4,657</b>	<b>6%</b>

## ● Full-year 2018: Expanding global workforce to support QIAGEN's development

Headcount information is made using certain assumptions regarding role and function. During 2018, these assumptions were updated and their classifications were changed accordingly.



Strong focus on execution and performance

2018: Delivered on objectives and created a stronger company

2019: Set to generate a solid performance

Committed to higher returns and disciplined capital deployment




---

3


- a. Supervisory Board Report on the Company's Annual Accounts (the "Annual Accounts") for Calendar Year 2018
  - b. Report of the Compensation Committee of the Supervisory Board for Calendar Year 2018
-





4

Adoption of the Annual Accounts for Calendar Year 2018  
(voting item)



5

## Reservation and dividend policy



6

Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2018 (voting item)



7

Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2018 (voting item)



8

Reappointment of the following seven Supervisory Directors of the Company for a one year term ending at the close of the Annual General Meeting in 2020 (voting item)

- a. Mr. Stéphane Bancel
- b. Dr. Håkan Björklund
- c. Dr. Metin Colpan
- d. Prof. Dr. Ross L. Levine
- e. Prof. Dr. Elaine Mardis
- f. Mr. Lawrence A. Rosen
- g. Ms. Elizabeth E. Tallett

## Supervisory Board members



**Dr. Håkan Björklund**  
Chairman  
Joined 2017



**Stéphane Bancel**  
Joined 2013



**Metin Colpan, Ph.D.**  
Joined 2004



**Elaine Mardis, Ph.D.**  
Joined 2014



**Ross Levine, M.D.**  
Joined 2016



**Lawrence A. Rosen**  
Joined 2013



**Elizabeth E. Tallett**  
Joined 2011

- Six new Board members appointed since 2011 with broad range of experience



9

Reappointment of the following two Managing Directors of the Company for a term ending on the date of the Annual General Meeting in 2020 (voting item)

- a. Mr. Peer M. Schatz
- b. Mr. Roland Sackers



10

Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2019 (voting item)





11

Authorization of the Supervisory Board,  
until December 17, 2020 to:

- a. issue a number of Common Shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of shares issued and outstanding in the capital of the Company as at December 31, 2018, as included in the Annual Accounts for Calendar Year 2018, (voting item)



11

Authorization of the Supervisory Board,  
until December 17, 2020 to:

- b. restrict or exclude the pre-emptive rights with respect to issuing Common Shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2018, (voting item)



11

Authorization of the Supervisory Board,  
until December 17, 2020 to:

- c. solely for the purpose of strategic transactions such as mergers, acquisitions or strategic alliances, to restrict or exclude the pre-emptive rights with respect to issuing additional Common Shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2018, (voting item)



12

Authorization of the Managing Board, until December 17, 2020, to acquire shares in the Company's own share capital (voting item)



13

Resolution to amend the Company's Articles of Association (voting item)




14

Questions



15

Closing



Thank you



Wir möchten Sie herzlich zu unserem  
QIAGEN Private Investor Day 2019

am 27. September 2019  
von ca. 11:00 – 16:00

bei QIAGEN in  
Hilden, Deutschland einladen

Kontakt:  
Alexandra König  
+49 2103 29 11709  
E-Mail: [alexandra.koenig@qiagen.com](mailto:alexandra.koenig@qiagen.com)

